1. BMS Reports EMA’s Validation of MAA for Idecabtagene Vicleucel (Ide-cel, bb2121) and CC-486 Published: May 22, 2020 | Tags: bb2121, BMS ,CC-486, EMA, ide-cel Idecabtagene, Vicleucel MAA 2. Gilead Plans […]readmore
Tags : Synlogic
Shots: Synlogic regains all rights to develop Synthetic Biotic medicines for all effectors targeting IBD. The termination allows Synlogic to deploy its expertise in strain engineering, quantitative biology, regulatory, and […]readmore
